C7 Activators
C7 activators are a classification of chemical agents that are characterized by their specific interaction with a subset of cellular or molecular pathways, typically involving the modulation of a particular type of protein or enzyme function within the context of biochemical processes. These activators are defined by their ability to engage with the seventh carbon (C7) in certain molecular structures, which can play a pivotal role in the regulation of various biochemical cascade reactions. The significance of the C7 position in organic molecules arises from the fact that it is often a key site for chemical reactivity, enabling the activators to initiate or enhance a series of reactions that can have profound impacts on the molecular dynamics within cells.
The chemistry of C7 activators is complex and diverse, as it encompasses a wide array of molecular frameworks and functional groups capable of interacting with the C7 position in different chemical contexts. The specificity of these activators often depends on the precise configuration of the target molecules, as well as the presence of particular functional groups that can facilitate the desired interaction. For example, in certain cases, the C7 position may be part of a conjugated system or located within a ring structure, which can influence the activator's mode of action. Moreover, the activator molecules themselves are often designed or identified based on their chemical stability, reactivity, and selectivity, with a careful consideration of how they interact with their target molecules without engaging in unwanted side reactions. In essence, the C7 activators are a testament to the intricate interplay between structure and function that underlies chemical reactivity and specificity in biological systems.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that directly activates C7 by inhibiting negative regulators, such as PKC and GSK3β. By blocking these kinases, staurosporine unleashes the full activation potential of C7, leading to enhanced functional activity. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid enhances C7 activity by selectively inhibiting protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), critical negative regulators of C7 signaling. The inhibition of PP1 and PP2A prevents the dephosphorylation of C7, thereby promoting its persistent activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphatidylinositol 3-kinase (PI3K) inhibitor that activates C7 by augmenting the PI3K-AKT pathway. By inhibiting PI3K, Wortmannin prevents the degradation of C7 and enhances its functional activity through sustained activation of downstream signaling cascades. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
H-89 is a selective protein kinase A (PKA) inhibitor that activates C7 by blocking the inhibitory effects of PKA. By inhibiting PKA, H-89 prevents the phosphorylation of C7, leading to increased functional activity through the removal of inhibitory constraints on C7 signaling. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Gö6976 enhances C7 activity by inhibiting protein kinase C (PKC). PKC negatively regulates C7 through phosphorylation events, and Gö6976 disrupts this inhibition, resulting in the activation of C7 and increased functional activity within the cellular context. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 indirectly enhances C7 activity by inhibiting TGF-β receptor I (ALK5) and suppressing the TGF-β signaling pathway. As C7 is negatively regulated by TGF-β, the inhibition of ALK5 by SB-431542 indirectly promotes the functional activation of C7 within the cellular environment. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I activates C7 by inhibiting PKC, a negative regulator of C7 signaling. Through the suppression of PKC, Bisindolylmaleimide I removes inhibitory constraints on C7, leading to increased functional activity within the cellular context. | ||||||
Hesperidin | 520-26-3 | sc-205711 sc-205711A | 25 g 100 g | $80.00 $200.00 | 5 | |
Hesperidin enhances C7 activity by activating the PI3K-AKT pathway. By promoting the phosphorylation of AKT, Hesperidin indirectly activates C7 and augments its functional activity through the stimulation of downstream signaling events within the PI3K-AKT pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 enhances C7 activity by inhibiting Src family kinases (SFKs). SFKs negatively regulate C7 through phosphorylation events, and PP2 disrupts this inhibition, resulting in the activation of C7 and increased functional activity within the cellular context. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib activates C7 by inhibiting MEK, a kinase involved in the MAPK/ERK pathway. Through MEK inhibition, Trametinib prevents the downstream phosphorylation of C7, leading to enhanced functional activity within the MAPK/ERK signaling cascade. | ||||||